{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.1","upperLimit":"18.9","value":"6.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"Duration of response DR is defined as the time from the date of first response after treatment to the date of disease progression Patients who have died for any cause or are alive without progression are censored at the date the patient is last know to be progression-free.\n\nDuration of response DR is defined as the time from the date of first response after treatment to the date of disease progression or death for any cause. Patients who are alive without progression are censored at the date the patient is last know to be progression-free.","dispersionType":"90% Confidence Interval","groups":[{"description":"30 mg three days a week (Mondays, Wednesdays and Fridays).\n\n1 cycle was 28 days\n\nDose modifications for attributable toxicities allowed for reduction to:\n\n* 25 mg, 20 mg three times a week every week\n* Or 20 mg three times a week every other week. No dose re-escalation was allowed.\n\n  * The protocol was amended on 6/15/2010 because of concerns of toxicity to allow a starting dose of 25 mg; 12/36 (33%) patients were enrolled on the 25 mg dose.\n\nLBH589","id":"OG000","title":"LBH589"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Assessed after 2nd cycle and then every subsequent cycle for 6 cycles and then every 3 months. If taken off treatment at cycle 2 for disease progression, assessed every 3 months. The median (range) follow up from treatment start is 7.7 month (0.9 - 29.7).","title":"Median Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}